Conclusions
In this study we demonstrated that the PTP4A3 phosphatase could be a new therapeutic target for COVID-19-related ARDS. We conclude that the novel inhibitor KVX-053, also known as JMS-053, exhibits potential to become an effective drug for the treatment of ARDS.